TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is a Telix Pharmaceuticals Limited program in metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Its next catalyst is a Readout in Q2 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Sponsor: Telix Pharmaceuticals Limited (TLX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is a Readout in Q2 2027.
No FDA decision for TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is in our archive yet.
In our records TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is under review or in development for metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer.
Telix Pharmaceuticals Limited (TLX).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.